Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Brain tumor drug trial halted before results

NCT ID NCT01068782

Disease control Sponsor: Exelixis Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested the drug cabozantinib in 19 people with a severe type of brain tumor (grade IV astrocytic tumors) that had come back after initial treatment. The goal was to see if the drug could shrink tumors or slow progression. However, the company stopped the trial early for business reasons, so no effectiveness data were collected. The study only provides safety information from a small group.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
cabozantinib (XL-184)
What this could lead to
If it had succeeded, this could have pointed toward a new treatment option for recurrent brain tumors.
What could go wrong
The trial was terminated early for business reasons before any efficacy data were collected, so we don't know if cabozantinib works for this cancer. Only 19 people enrolled, making results very limited.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

19 people

The number who actually took part.

Start date

Apr 2010

Finished

Oct 2013

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * The subject has histologically confirmed diagnosis at any time of grade IV astrocytic tumor as determined by the investigator. Tumor samples will be required for pathology review. * The subject has received prior standard radiation for any grade astrocytic tumor. * The subject has received prior temozolomide (Temodar) therapy * The subject has had one or two progressions as grade IV astrocytic tumor from any grade, as determined by investigator * The subject must have a qualifying brain MRI scan within a specific timeframe prior to start of study treatment * For subjects with recent tumor resection or biopsy, starting on study must occur a specified amount of time after the surgery and the subject must have recovered from the effects of surgery * The subject has a Karnofsky Performance Status ≥ 70% and has the ability to swallow whole capsules * The subject is capable of understanding the informed consent and has signed the informed consent document * The subject has adequate organ and marrow function * Sexually active subjects (male and female) must agree to use medically accepted methods of contraception during the course of the study and for 6 months following discontinuation of study treatment * The subject has had no other diagnosis of malignancy (certain exceptions apply) * Female subjects of childbearing potential must have a negative pregnancy test at screening Exclusion Criteria: * The subject has received certain prior anticancer therapies within a certain amount of time before starting study treatment * The subject is receiving warfarin (or other coumarin derivatives) and is unable to switch to low molecular weight heparin * The subject has evidence of acute intracranial or intratumoral hemorrhage either by MRI or CT scan. Subjects with resolving hemorrhage changes, punctate hemorrhage, or hemosiderin are eligible * The subject is unable to undergo MRI scan (eg, has pacemaker) * The subject has received enzyme-inducing anti-epileptic agents within a certain time prior to starting study treatment (eg, carbamazepine, phenytoin, phenobarbital, primidone) * The subject has not recovered to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v3.0 Grade ≤ 1 from AEs (except alopecia and lymphopenia) due to surgery, or other medications that were administered prior to study start * The subject has evidence of unhealed wounds * The subject is pregnant or breast-feeding * The subject has serious intercurrent illness or a recent history of serious disease * The subject has inherited bleeding diathesis or coagulopathy (disease affecting how blood clots) with the risk of bleeding * The subject has a history of any medical or surgical conditions (eg, stomach or intestinal surgery or resection) that would potentially interfere with or alter gastrointestinal function * The subject has a history of idiopathic pulmonary fibrosis or interstitial lung disease * The subject has received any live virus vaccine or any inactivated vaccine within a certain amount of time before starting study treatment

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Astrocytic tumors are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

astrocytic tumor astrocytoma (excluding glioblastoma) brain cancer glioblastoma glioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Astrocytic tumors

Contacts and locations

Locations

  • Study site

    Birmingham, Alabama, 35294, United States

  • Study site

    Encinitas, California, 92024, United States

  • Study site

    Pleasant Hill, California, 94523, United States

  • Study site

    Chicago, Illinois, 60611, United States

  • Study site

    Chicago, Illinois, 60637, United States

  • Study site

    Boston, Massachusetts, 02115, United States

  • Study site

    Detroit, Michigan, 48202, United States

  • Study site

    Minneapolis, Minnesota, 55407, United States

  • Study site

    Amherst, New York, 14226, United States

  • Study site

    Rochester, New York, 14642, United States

  • Study site

    Cleveland, Ohio, 44195, United States

  • Study site

    Hershey, Pennsylvania, 17033, United States

  • Study site

    Dallas, Texas, 75246, United States

  • Study site

    Dallas, Texas, 75426, United States

  • Study site

    San Antonio, Texas, 78229, United States

  • Study site

    Charlottesville, Virginia, 22908, United States

  • Study site

    Seattle, Washington, 98122, United States

  • Study site

    Calgary, Alberta, Canada

  • Study site

    Montreal, Quebec, Canada